Oncology Drug Reference Sheet: Trilaciclib
On February 12, 2021, the U.S. Food and Drug Administration approved trilaciclib (CoselaTM), a parenteral inhibitor of cyclin-dependent kinase, to prevent myelosuppression when administered prior to chemotherapy administration. The approval is currently limited to the use of trilaciclib before treatment with platinum- and etoposide-containing regimens and topotecan-containing regimens for treatment of extensive-stage small cell lung cancer.
Find Your Voice With ONS’s Leadership Development Committee
Dedication to their patients and each other and an innate passion unrivaled by most other professions are two of the reasons why oncology nurses make great leaders—I know that from my daily work with colleagues both near and far as well as my experience as part of ONS’s Leadership Development Committee.
FDA Grants Accelerated Approval to Amivantamab-Vmjw for Metastatic NSCLC
On May 21, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to amivantamab-vmjw (Rybrevant™), a bispecific antibody directed against epidermal growth factor receptor (EGFR) and MET receptor, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. FDA also approved the Guardant360® CDx as a companion diagnostic.
- Read more about FDA Grants Accelerated Approval to Amivantamab-Vmjw for Metastatic NSCLC
- Add new comment
The COVID-19 Pandemic Fast-Tracked Our Growth as Nurses
For the past 15 months, healthcare providers across the country risked their lives to care for those who needed us most. After spending more than a year at the forefront of a global health crisis, many of us, naturally, harbor feelings of stress and anxiety. Now that the world is returning to something resembling normal, we can pause, reflect, and observe how much we’ve all grown throughout this experience.
What the Evidence Says About Dance/Movement Therapy in Cancer Care
Dance/movement therapy is a complementary modality that may help patients manage cancer and its treatment-associated symptoms. Based on the concept that mind, body, and spirit are interconnected, it combines the communicative elements of dance and movement with other body-focused activities—such as guided imagery, mindfulness, breath awareness, and play—to create an emotionally inviting environment where participants can share feelings and experiences.
FDA Approves Nivolumab for Resected Esophageal or GEJ Cancer
On May 20, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) for patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy.
Vivek Murthy Confirmed as U.S. Surgeon General, Again
Known as the nation’s doctor, the U.S. surgeon general provides scientific information and oversees the U.S. Public Health Service’s Commissioned Corps: more than 6,000 professionals who promote health across the United States. Vivek Murthy, MD, MBA, who served as surgeon general under President Barack Obama, once again assumed his post as the nation’s doctor in March 2021 and said he will prioritize addressing the COVID-19 coronavirus pandemic and opioid epidemic during his second tenure. Murthy was appointed during his transition as the chair of the COVID-19 advisory board.
Oncology Nurses Are Making a Difference in Policy and Advocacy
A shining light to guide a burgeoning field—often referred to as “the lady with the lamp”—Florence Nightingale was a revolutionary figure in nursing, transforming care by simple but radical actions. Through scientific research she showed that sanitation and healthy diets improved patient outcomes, and through advocacy she fought for access to those conditions for all of her patients. She modeled the way for nurse advocates throughout history and into today.
Share These Resources to Increase COVID-19 Vaccination Rates
President Joe Biden committed to getting at least 70% of U.S. adults their first dose of the COVID-19 coronavirus vaccine and achieve 160 million fully vaccinated American adults by July 4, 2021. However, one in five Americans reported that they aren’t planning to get vaccinated. To dispel public fear and increase understanding, several U.S. health agencies provided multiple resources to educate patients and providers on vaccine distribution and efficacy.
Text Messaging Reduces Disparities in Colorectal Cancer Screening
A series of text reminders to complete an at-home fecal immunochemical test increased screening completion rates by nearly 20%, researchers reported in study findings published in the Journal of General Internal Medicine. The results are particularly encouraging because almost 90% of the participants were Black, a population that typically has low screening adherence rates but higher incidence of and mortality from colorectal cancer.